Active ingredient
Liraglutide
Liraglutide produces ~8% mean weight loss at 56 weeks (SCALE) — the lowest of the GLP-1 weight-management agents. Daily injection vs weekly is the main reason patients still choose it: shorter half-life means faster stoppage if side effects emerge.
Brand names + indications
Liraglutide is sold under 2 brand names, each with its own indication + maximum dose.
How it works
Liraglutide is a once-daily GLP-1 receptor agonist with a 13-hour half-life — shorter than the weekly options. The shorter duration requires daily injection but offers more precise control over peak/trough levels.
Pivotal trial efficacy
−8.0%
Mean weight loss
The pivotal phase-3 trial for Liraglutide is SCALE Obesity and Prediabetes, which showed mean body-weight reduction at the maintenance dose.